KIT and hepatocellular carcinoma: Biomarkers attempting to predict the response of patients to the standard sorafenib treatment failed in clinical trials, nor was c-Kit predictive as a pharmacological target of the drug.18 The expression of c-MET, however, was correlated with the response to tivantinib and overall survival,19 indicating that generating companion diagnostics biomarkers for drugs for the treatment of HCC is possible in principle.